Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

androgen receptor degrader AC176

An orally bioavailable androgen receptor (AR) chimeric degrader, with potential antineoplastic activity. Upon oral administration, AR degrader AC176 targets and degrades AR, thereby preventing AR-mediated signaling and inhibiting the proliferation of AR-overexpressing tumor cells. AR, a hormone-regulated transcription factor, plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AR degrader AC176
Code name:	AC 176 AC-176 AC0176 AC176

androgen receptor degrader AC176

Search NCI's Drug Dictionary